NEWS Life Molecular Imaging and SOFIE announce Neuraceq® availability in Houston 9 January 2024 LEARN MORE
NEWS CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan 22 November 2023 LEARN MORE
NEWS Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China 13 October 2023 LEARN MORE
NEWS Life Molecular Imaging announces presentation of new scientific data at the European Association of Nuclear Medicine annual meeting 2023 5 September 2023 LEARN MORE
NEWS Life Molecular Imaging announces presentation of new scientific data at the Alzheimer’s Association International Conference 14 July 2023 LEARN MORE
NEWS Life Molecular Imaging Applauds FDA’s Full Approval of LEQEMBI® for Alzheimer’s Disease 6 July 2023 LEARN MORE
NEWS Life Molecular Imaging Announces Start of Phase 3 Study with [18F]Florbetaben in Cardiac Amyloid Light Chain (AL) Amyloidosis 7 February 2023 LEARN MORE
NEWS Life Molecular Imaging and Advanced Medical Support Announce a Strategic Partnership for the Production of Florbetaben (18F) at the American University of Beirut Medical Centre, Lebanon 25 January 2023 LEARN MORE
